Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease

American Journal of Geriatric Psychiatry

Volumn 11, Issue 2, 2003, Pages 146-159

  Matthews, Brandy ^a   Siemers, Eric R ^a,b   Mozley, P David ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN PERFUSION; BRAIN SIZE; CLINICAL TRIAL; COGNITION; CONTRAST RADIOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MARKER; DRUG WITHDRAWAL; ENTORHINAL CORTEX; FOOD AND DRUG ADMINISTRATION; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MEDLINE; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROTON NUCLEAR MAGNETIC RESONANCE; SCORING SYSTEM; SENILE PLAQUE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; VALIDATION PROCESS; VOLUMETRIC MAGNETIC RESONANCE IMAGING;

EID: 0037371280     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200303000-00005     Document Type: Article

References (77)

1. White L, Petrovitch H, Ross GW, et al: Prevalence of dementia in older Japanese-American men in Hawaii. JAMA 1996; 276:955-960
2. Jost BC, Grossberg GT: The natural history of Alzheimer's disease: a brain bank study. J Am Geriatr Soc 1995; 43:1248-1255
3. Smith GE, O'Brien PC, Ivnik RJ, et al: Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology 2001; 57:1467-1473
4. Schneider LS: Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med 2001; 17:337-358
5. Irizarry MC, Hyman BT: Alzheimer disease therapeutics. J Neuropathol Exp Neurol 2001; 60:923-928
6. Locascio JJ, Growdon JH, Corkin S: Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch Neurol 1995; 52:1087-1099
7. Whitehouse PJ, Kittner B, Roessner M, et al: Clinical trial designs for demonstrating disease-course-altering effects in dementia. Alzheimer Dis Assoc Disord 1998; 12:281-294
8. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
9. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
10. Weyer G, Erzigkeit H, Kanowski S, et al: Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr 1997; 9:123-138
11. Pena-Casanova J: Alzheimer's Disease Assessment Scale: cognitive and clinical practice. Int Psychogeriatr 1997; 9(suppl 1):105-114
12. Alexander GE, Furey ML, Grady CL, et al: Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Am J Psychiatry 1997; 154:165-172
13. Kaye JA, Swihart T, Howieson D, et al: Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997; 48:1297-1304
14. Mueller EA, Moore MM, Kerr DCR, et al: Brain volume preserved in healthy elderly through the eleventh decade. Neurology 1998; 51:1555-1562
15. Mielke R, Herholz K, Grond M, et al: Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging 1992; 13:93-98
16. Mozley PD, Schneider JS, Acton PD, et al: Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000; 41:584-589
17. Mozley LH, Gur RC, Mozley PD, et al: Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 2001; 158:1492-1499
18. Raskind MA, Peskind ER, Wessel T. et al: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54:2261-2268
19. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50:136-145
20. Khoury SJ, Weiner HL: Multiple sclerosis: what have we learned from magnetic resonance imaging studies? Arch Int Med 1998; 158:565-573
21. Jeffery DR: Relationship between disease activity and dose-response relationships with beta interferon therapies in the treatment of multiple sclerosis. J Neurol Sci 2000; 178:2-9
22. Scheltens P: Early diagnosis of dementia: neuroimaging. J Neurol 1999; 246:16-20
23. Bryant CA, Jackson SH: Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. Drugs Aging 1998; 13:211-222
24. Gur RC, Mozley PD, Gur RE, et al: Gender differences in age effect on brain atrophy measured by magnetic resonance imaging. Proc Natl Acad Sci U S A 1991; 88:2845-2849
25. Gur RE, Maany V, Mozley PD, et al: Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry, 1998; 155:1711-1717
26. Kohn MI, Tanna NK, Herman GT, et al: Analysis of brain and cerebrospinal fluid volumes with MR imaging, part I: methods, reliability, and validation. Radiology 1991; 178:115-122
27. Fox NC, Scahill RI, Crum WR, et al: Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999; 52:1687-1689
28. Fox NC, Cousens SD, Scahill R, et al: Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000; 57:339-344
29. Jack CR Jr, Petersen RC, Xu Y, et al: Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998; 51:993-999
30. Laakso MP, Lehtovirta M, Partanen K, et al: Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study. Biol Psychiatry 2000; 47:557-561
31. Hui F, Cavazos JE, Tien RD: Hippocampus: normal magnetic resonance imaging anatomy with volumetric studies. Neuroimaging Clin N Am 1997; 7:11-30
32. Golebiowski M, Barcikowska M. Pfeifer A: Magnetic resonance imaging-based hippocampal volumetry in patients with dementia of the Alzheimer type. Dement Geriatr Cogn Disord 1999; 10:284-288
33. Xu Y, Jack CR Jr, O'Brien PC, et al: Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000; 54:1760-1767
34. Frisoni GB, Laasko MP, Beltramello A, et al: Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology 1999; 52:91-100
35. Laakso MP, Soininen H, Partanen K, et al: MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 1998; 19:23-31
36. Xanthakos S, Krishnan KR, Kim DM, et al: Magnetic resonance imaging of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20:597-626
37. Watson C, Jack CR Jr, Cendes F: Volumetric magnetic resonance imaging: clinical applications and contributions to the understanding of temporal lobe epilepsy. Arch Neurol 1997; 54:1521-1531
38. Reivich M, Sokoloff L, Shapiro H, et al: Validation of an autoradiographic method for the determination of the rates of local cerebral glucose utilization. Trans American Neurological Association 1974; 99:238-240
39. Reivich M: Application of the deoxyglucose method to human cerebral dysfunction: the use of [2-18F] fluoro-2-deoxy-D-glucose in man. Neurosci Res Program Bull 1976; 14:502-504
40. Jelic V, Nordberg A: Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord 2000; 14(suppl1):S109-S113
41. Rapoport SI: Discriminant analysis of brain imaging data identifies subjects with early Alzheimer's disease. Int Psychogeriatr 1997; 9(suppl1):229-235
42. Mega MS, Chu T, Mazziotta JC, et al: Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease. Neuroreport 1999; 10:2911-2917
43. Mega MS, Chen SS, Thompson PM, et al: Mapping histology to metabolism: coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease. Neuroimage 1997; 5:147-153
44. Herholz K, Nordberg A, Salmon E, et al: Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999; 10:494-504
45. Herholz K, Perani D, Salmon E, et al: Comparability of FDG-PET studies in probable Alzheimer's disease. J Nucl Med 1993; 34:1460-1466
46. Mielke R, Herholz K, Grond M, et al: Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia 1994; 5:36-41
47. Alexander GE, Chen K, Pietrini P, et al: Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002; 159:738-745
48. Small GW, Ercoli LM, Silverman DH, et al: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 97:6037-6042
49. Desgranges B, Baron JC, de la Sayette V, et al: The neural substrates of memory-systems impairment in Alzheimer's disease: a PET study of resting brain glucose utilization. Brain 1998; 121:611-631
50. Signorini M, Paulesu E, Friston K, et al: Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG-PET: a clinical validation of statistical parametric mapping. Neuroimage 1999; 9:63-80
51. Minoshima S, Giordani B, Berent S, et al: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85-94
52. Reiman EM, Uecker A, Gonzalez-Lima F, et al: Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport 2000; 11:987-991
53. Meguro K, Blaizot X, Kondoh Y, et al: Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET: implications for Alzheimer's disease. Brain 1999; 122:1519-1531
54. Ibanez V, Pietrini P, Alexander GE, et al: Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology. 1998; 50:1585-1593
55. Yamaguchi S, Meguro K, Itoh M, et al: Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. J Neurol Neurosurg Psychiatry 1997; 62:596-600
56. Pietrini P, Furey ML, Alexander GE, et al: Association between brain functional failure and dementia severity in Alzheimer's disease: resting versus stimulation PET study. Am J Psychiatry 1999; 156:470-473
57. Matsuda H: Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 2001; 15:85-92
58. Jagust WJ, Eberling JL, Reed BR, et al: Clinical studies of cerebral blood flow in Alzheimer's disease. Ann New York Acad Sci 1997; 826:254-262
59. Masterman DL, Mendez MF, Fairbanks LA, et al: Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias. J Geriatr Psychiatry Neurol 1997; 10:15-21
60. Herholz K, Schopphoff H, Schmidt M, et al: Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 2002; 43:21-26
61. Ishii K, Sasaki M, Sakamoto S, et al: Tc-99m ethyl cysteinate dimer SPECT and 2-[F-18] fluoro-2-deoxy-D-glucose PET in Alzheimer's disease: comparison of perfusion and metabolic patterns. Clin Nucl Med 1999; 24:572-575
62. Scheltens P: Imaging Alzheimer's disease. The World Alzheimer Congress 2000. Stockholm, Sweden
63. Adalsteinsson E, Sullivan EV, Kleinhans N, et al: A longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000; 355:1696-1697
64. Schuff N, Amend D, Ezekiel F, et al: Changes of hippocampal Nacetyl aspartate and volume in Alzheimer's disease: a proton MR spectroscopic imaging and MRI study. Neurology 1997; 49:15131521
65. Kantarci K, Jack CR Jr, Xu YC, et al: Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 2000; 55:210-217
66. Skovronsky DM, Zhang B, Kung MP, et al: In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 97:7609-7614
67. Wang Y, Klunk WE, Huang G-F, et al: Synthesis and evaluation of a radioiodinated benzothiazole derivative as a radioligand for invivo quantitation of β-amyloid deposits in aging and Alzheimer's disease. Journal of Labeled Compounds and Radiopharmaceuticals 2001; 44(suppl1):S239-S241
68. Zhuang ZP, Kung MP, Hou C, et al: Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001; 44:1905-1914
69. Klunk WE: Biological markers of Alzheimer's disease. Neurobiol Aging 1998; 19:145-147
70. Klunk WE, Pettegrew JW, Abraham DJ: Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem 1989; 37:1273-1281
71. Klunk WE, Debnath ML, Pettegrew JW: Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 1994; 15:691-698
72. Klunk WE, Wang Y, Huang G-F, et al: Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001; 69:1471-1484
73. Mathis CA, Bacskai BJ, Kajdasz ST, et al: A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002; 12:295-298
74. Mathis CA, Holt DP, Wang Y, et al: Lipophilic 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease. Journal of Labelled Compounds and Radiopharmaceuticals 2001; 44(suppl1):S26-S28
75. Shoghi-Jadid K, Small GW, Agdeppa ED, et al: Localization ofneurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:24-35
76. Engler H, Nordberg A, Blomquist G, et al: First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects (abstract). Neurobiol Aging 2002; 23:S429
77. Wengenack TM, Curran GL, Poduslo JF: Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 2000; 18:868-872